rasburicase (Elitek)

06/01/2012 - "Rasburicase is highly effective for prevention and management of hyperuricemia in adults at risk for TLS. "
01/01/2008 - "A single dose of rasburicase is highly effective and well tolerated in the treatment of hyperuricemia in selected CKD patients."
01/01/2006 - "Although further pharmacoeconomic data would be useful, rasburicase was most cost effective for the prevention of hyperuricemia in children and for treatment of this condition in adults. "
09/01/2010 - "Shorter courses or smaller doses of rasburicase than those recommended may be effective in reducing hyperuricemia in some patients, but it is important to recognize that the alternative dosing still awaits validation. "
04/01/2014 - "These results demonstrated that recombinant rasburicase that is indigenously developed is effective for prevention and management of hyperuricemia in patients who are at high risk of developing TLS."

02/01/2009 - "Rasburicase is very effective in the prevention of acute tumour lysis syndrome. "
01/01/2013 - "One for the road! A study to assess the efficacy of single low-dose regimen of rasburicase in controlling hyperuricaemia in patients with tumour lysis syndrome due to haematological malignancies."
06/01/2012 - "A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome."
12/01/2011 - "Recently, a number of studies have demonstrated the effectiveness of a single reduced dose of rasburicase for the management of tumor lysis syndrome (TLS) in adults. "
03/01/2014 - "Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome."

11/01/2009 - "This study in Japanese patients evaluated the efficacy, safety, and pharmacokinetic profile of rasburicase in pediatric patients with hematologic malignancies. "
05/01/2015 - "To define the efficacy and safety of low-dose rasburicase in children from south India with hematologic malignancies. "
05/01/2015 - "Low-dose rasburicase in hematologic malignancies."
11/01/2009 - "Patients aged <18 years at high risk for TLS, with newly diagnosed hematologic malignancies, were randomized to intravenous rasburicase 0.15 mg/kg/day (n = 15) or 0.20 mg/kg/day (n = 15) for 5 days. "
06/01/2006 - "We collected retrospective data for 11 adults with hematologic malignancies who received a single 6-mg dose of rasburicase. "

05/01/2015 - "Low-dose rasburicase (0.1-0.15 mg/kg) is safe and effective in reducing PUA in Indian children with lymphoid malignancies, and thus it may reduce the risk of renal failure from TLS."
08/01/2007 - "Rasburicase can reverse renal insufficiency. "
11/01/2013 - "A TLS strategy incorporating rasburicase prior to cytoreductive chemotherapy proved safe and effective in preventing new onset renal failure and was associated with a significant improvement in GFR. "
01/01/2008 - "[Efficacy of rasburicase therapy in obstructive renal failure secondary to urolithiasis: a novel therapeutic option]."
01/01/2008 - "But we also could postulate that rasburicase can act in urinary tract, fragmentating renal calculi, promoting relief of obstructive uropathy and the resolution of renal failure. "

08/01/2013 - "It suggests that the single-dose rasburicase is clinically effective and cost efficient for the prophylaxis of high-risk TLS and the treatment of hyperuricaemia in adult patients with cancer. "
04/01/2002 - "Rasburicase is a safe and effective agent in the prevention or treatment of hyperuricaemia in cancer patients."
04/01/2002 - "To date, rasburicase has been tested in four clinical trials conducted in patients with cancer (primarily haematological malignancies). "
01/01/2015 - "Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy."
10/01/2008 - "Rasburicase: future directions in tumor lysis management."